ROCR Value Based Program Act
- Bill Number
- H.R. 2120
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-03-14: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2026-07-10T08:05:52Z
AI-Generated Summary
Purpose of the Legislation
This bill, titled the "Radiation Oncology Case Rate Value Based Program Act of 2025" (or "ROCR Value Based Program Act"), aims to improve Medicare payments for radiation therapy services used to treat cancer. It establishes a new bundled payment system to create stable and fair reimbursements, encourage high-quality and efficient care, reduce disparities in access (especially for rural or underserved patients), promote modern technology, and control overall Medicare spending on these services. Additionally, it allows free or discounted transportation for patients receiving radiation therapy without violating anti-fraud laws.
Key Provisions
- Establishment of the ROCR Program:
- Creates a mandatory program under Medicare Part B for per-episode payments (bundled amounts covering an entire course of treatment) for radiation therapy services for 15 specific cancer types (e.g., breast, lung, prostate, bone/brain metastases).
- Payments are split into professional (doctor-led planning and oversight) and technical (equipment, staff, and facility costs) components, paid at 80% by Medicare with 20% coinsurance for patients.
- Episodes of care last 90 days (or 30 days for bone/brain metastases treatment), starting from treatment planning and ending after delivery.
- Initial half-payment issued within 30 days of first treatment; second half at the end of the scheduled course or episode timeline.
- Payments are site-neutral (same amount whether in a hospital or doctor's office) and exempt from budget neutrality rules, meaning savings from this program won't reduce other Medicare payments.
- Payment Adjustments and Incentives:
- Base rates derived from 2021 Medicare data, updated annually for inflation (using Medicare Economic Index for professional and Hospital Market Basket for technical components) with a "payment floor" to prevent cuts.
- Geographic adjustments for local costs; a savings adjustment to achieve Medicare cost reductions.
- Health equity add-on: $500 per episode (increasing by $10 yearly) for patients reporting transportation insecurity (via a standard diagnosis code), paid only to technical providers to fund non-luxury transport (e.g., rideshares, public transit). Requires documentation and can't replace other aid programs.
- Quality incentives: +1% payment boost for accredited providers in the first two years; -2.5% penalty after two years for non-accredited ones (accreditation by groups like American College of Radiology; exceptions for low-resource or rural providers, capped at 10% of total participants).
- Special handling for incomplete episodes (e.g., patient death or switch providers): Revert to standard fee-for-service payments.
- Participation and Exclusions:
- Mandatory for most Medicare-participating radiation therapy providers (hospitals) and suppliers (physician practices or freestanding centers), but optional if in other state-based innovation models; hardship exemptions for disasters or access issues.
- Excludes certain therapies initially (e.g., proton beam, brachytherapy) for 12 years, inpatient services, and non-radiation items like chemotherapy or durable medical equipment.
- New technologies get separate payments until integrated (after 12 years, based on stakeholder input); transitional payments for adaptive planning (adjusting treatment mid-course).
- Transportation Exception:
- Amends the anti-kickback statute to allow free/discounted non-ambulance transport for established radiation patients within 75 miles (or any distance in rural areas), if uniformly offered, not marketed, and costs not shifted to Medicare or patients.
- Eligible entities include providers/suppliers or their agents not primarily in healthcare supply.
- Reporting and Oversight:
- Secretary (CMS head) must issue regulations within 1 year via public comment process; no payment rate cuts until then.
- Government Accountability Office reports: One in 3 years on rural access and "radiation therapy deserts" (areas with insufficient services relative to cancer needs), suggesting grants/loans for tech upgrades; another in 7 years evaluating program impacts, access, and potential expansions (e.g., to Medicare Advantage).
- Other Rules:
- Providers can offer installment plans for patient coinsurance but can't use them for marketing.
- Excludes ROCR participants from the Merit-based Incentive Payment System (MIPS), a quality-reporting program for doctors.
- No changes to patient coinsurance for equity add-ons.
Significant Changes to Existing Law
- New Payment Model: Replaces fragmented fee-for-service and hospital outpatient payments with bundled per-episode rates, addressing historical issues like volatile pricing for expensive equipment and undervalued expertise (as noted in 2017 CMS reports on a prior failed model).
- Budget Neutrality Exemption: Savings from ROCR won't offset other Medicare physician or outpatient payments, potentially increasing overall program costs initially.
- Anti-Kickback Amendment: Adds a specific exception for radiation patient transport, expanding safe harbor rules beyond general medical transport to target cancer care access.
- MIPS Exclusion: Removes radiation providers/suppliers from MIPS penalties/rewards, simplifying reporting under the new model.
- Coinsurance Flexibility: Introduces payment plans for bundled coinsurance, a new option not previously specified for these services.
Potential Impacts
- Government Agencies (CMS): Requires quick rulemaking, data analysis for rates/adjustments, and monitoring for equity/quality; could save Medicare money long-term through efficiency but increase administrative workload. Comptroller General reports may lead to further policy tweaks or funding for rural tech.
- Citizens (Medicare Beneficiaries): Improves access to radiation therapy near home, especially for ~60% of cancer patients needing it; equity payments and transport exceptions reduce barriers like travel costs in rural/underserved areas. Potential for shorter, higher-quality treatments but unchanged coinsurance (20%) may burden low-income patients without plans.
- Healthcare Providers/Suppliers: Shifts incentives from volume to value, rewarding accreditation and equity efforts; mandatory participation could strain small/rural facilities, but exemptions and floors protect against deep cuts. Encourages tech adoption but delays integration of new modalities.
- International Relations: No direct impacts; focuses solely on U.S. Medicare policy.
Main Stakeholders Affected
- Medicare Enrolled Cancer Patients: Primary beneficiaries, gaining better access and support for completing treatments without transportation hurdles.
- Radiation Therapy Providers and Suppliers: Hospitals, physician practices, and freestanding centers must adapt to bundled payments; incentives for quality/accreditation benefit larger/accredited ones, while rural/low-volume get protections.
- CMS and Federal Oversight Bodies: Responsible for implementation, rate-setting, and evaluations; interacts with stakeholders like oncology societies.
- Radiation Oncology Organizations: Groups like American Society for Radiation Oncology provide input on standards, rates, and new tech; accreditation bodies set quality benchmarks.
- Rural/Underserved Communities: Targeted for equity measures and access reports, potentially gaining from suggested grants/loans for equipment.
- Taxpayers/Medicare Program: Bear costs of non-neutral savings but benefit from controlled spending on $4.2 billion annual radiation services.
Notable Legal, Constitutional, or Political Implications
- Legal: Amends the Social Security Act (Titles XI and XVIII) to add a new section (1899C) and revise civil monetary penalties/anti-kickback rules, ensuring compliance with fraud laws while enabling patient aids. Relies on notice-and-comment rulemaking (standard under Administrative Procedure Act) for flexibility in rates/exemptions. Definitions (e.g., "episode of care," "new technology") clarify scope but allow Secretary discretion, potentially inviting future challenges if rates seen as arbitrary.
- Constitutional: No apparent issues; aligns with Congress's spending power under Article I for Medicare reforms. Equity provisions promote equal protection by addressing disparities without mandating benefits.
- Political: Bipartisan introduction (by Reps. Fitzpatrick, Panetta, Joyce, Tonko) signals broad support for cancer care access amid rising Medicare costs. Emphasizes value-based care, echoing broader healthcare trends, but mandatory elements and non-neutrality could spark debate on fiscal responsibility. Reports may influence future bills on rural health or Medicare Advantage expansions.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Fitzpatrick, Brian K. [R-PA-1]
Cosponsors (35)
Rep. Panetta, Jimmy [D-CA-19], Rep. Joyce, John [R-PA-13], Rep. Tonko, Paul [D-NY-20], Rep. Stevens, Haley M. [D-MI-11], Rep. Peters, Scott H. [D-CA-50], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Cohen, Steve [D-TN-9], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Scholten, Hillary J. [D-MI-3], Rep. Kim, Young [R-CA-40], Rep. Mullin, Kevin [D-CA-15], Rep. Carbajal, Salud O. [D-CA-24], Rep. Dingell, Debbie [D-MI-6], Rep. Balderson, Troy [R-OH-12], Rep. Crenshaw, Dan [R-TX-2], Rep. Bilirakis, Gus M. [R-FL-12], Rep. Salazar, Maria Elvira [R-FL-27], Rep. Lieu, Ted [D-CA-36], Rep. Bentz, Cliff [R-OR-2], Rep. Pfluger, August [R-TX-11], Rep. Davis, Donald G. [D-NC-1], Rep. Walkinshaw, James R. [D-VA-11], Rep. Kiggans, Jennifer A. [R-VA-2], Rep. McBride, Sarah [D-DE-At Large], Rep. Tran, Derek [D-CA-45], Rep. Clarke, Yvette D. [D-NY-9], Rep. LaLota, Nick [R-NY-1], Rep. Ellzey, Jake [R-TX-6], Rep. Lee, Susie [D-NV-3], Rep. Evans, Gabe [R-CO-8], Rep. Cisneros, Gilbert Ray [D-CA-31], Rep. Foushee, Valerie P. [D-NC-4], Rep. Wasserman Schultz, Debbie [D-FL-25], Rep. DelBene, Suzan K. [D-WA-1], Rep. Perez, Marie Gluesenkamp [D-WA-3]
Recent Actions
- 2025-03-14: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-03-14: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-03-14: Introduced in House
- 2025-03-14: Introduced in House
Bill Versions
- Radiation Oncology Case Rate Value Based Program Act of 2025 — issued 2025-03-14 — PDF (51 pages)